Herpes Simplex: Cold Sores and Genital Herpes Management

Clinical Overview

Herpes simplex virus (HSV) causes recurrent vesicular eruptions affecting oral, genital, and occasionally extragenital locations, characterized by prodromal symptoms preceding grouped vesicles on erythematous base. HSV-1 predominantly causes orofacial herpes (cold sores), while HSV-2 predominates in genital disease, though both types can affect either location. Approximately 60-90% of the global population carries HSV-1 seropositivity, with clinical manifestations ranging from asymptomatic shedding to severe primary infections with systemic symptoms. Primary infection typically occurs in childhood for HSV-1, characterized by more severe symptoms, prolonged course, and greater risk of complications compared to recurrent episodes. Recurrent herpes reflects periodic viral reactivation from latent infection in sensory nerve ganglia, occurring in response to immune suppression, stress, trauma, or other triggering factors. Antiviral therapy with nucleoside analogs dramatically reduces symptom duration, viral shedding, and transmission risk, making early recognition and treatment important clinical goals. Suppressive therapy prevents recurrent episodes in frequently affected individuals, improving quality of life and reducing transmission risk.

Epidemiology

Herpes simplex virus infection represents one of the most prevalent human infections, with HSV-1 seroprevalence exceeding 70% globally and HSV-2 seroprevalence of 15-20% in developed nations and up to 40-60% in developing countries. Primary infection typically occurs in early childhood for HSV-1, transmitted through contact with saliva or secretions. Genital HSV-2 transmission occurs predominantly in sexually active adults, with incidence of initial genital infection approximately 1% annually among sexually active populations. Recurrent orofacial herpes affects approximately 30-40% of HSV-1 seropositive individuals, occurring less frequently in younger age groups. Recurrent genital herpes occurs in approximately 50% of HSV-2 seropositive individuals, with frequency decreasing over time (mean of 4-5 recurrences yearly in first year, declining to 0-1 recurrences yearly within 5 years). Males with genital herpes demonstrate slightly higher recurrence frequency compared to females. Immunocompromised individuals including HIV-positive patients with CD4 less than 50 cells/microliter and organ transplant recipients demonstrate markedly increased frequency and severity of recurrent disease, with some patients experiencing near-continuous ulceration.

Pathophysiology

Herpes simplex virus infection begins with viral attachment to cell surface through viral glycoprotein G binding to heparan sulfate or nectin-1 and -4 receptors, followed by membrane fusion and viral entry. The virus replicates rapidly within epithelial cells, triggering inflammatory response with neutrophil and T-lymphocyte infiltration. Viral proteins disrupt normal cellular functions and induce programmed cell death (apoptosis), creating areas of epithelial necrosis that coalesce into vesicles containing viral particles and inflammatory fluid. Regional lymphadenopathy develops as virus spreads to draining lymph nodes triggering specific immune responses. Viral glycoproteins trigger both humoral and cellular immune responses, with cytotoxic T-lymphocytes critical for controlling acute infection and reducing recurrence frequency. Following acute infection resolution, virus retreats to sensory nerve cell bodies in trigeminal ganglia (for orofacial) or sacral ganglia (for genital herpes), where it becomes dormant. Periodic viral reactivation reflects breakdown in local immune suppression, with reactivated virus traveling along sensory nerves to dermatome distribution of initial infection. Recurrent disease involves reactivation and dissemination through dorsal root ganglia, causing productive infection with shed of infectious particles through epithelial ulceration. HSV-specific immune response includes IgG antibodies neutralizing viral infectivity, IgM antibodies in primary infection, and cellular immunity critical for prevention of severe disease and recurrence. Immunocompromised individuals demonstrate dramatically reduced T-cell function, allowing unchecked viral replication and more severe, prolonged disease.

Clinical Presentation

Primary herpes simplex infection typically causes more systemic symptoms than recurrent episodes, with fever, malaise, myalgias, headache, and regional lymphadenopathy preceding or accompanying skin lesions. Oral herpes presents with gingivostomatitis characterized by edematous, erythematous gingiva and multiple oral ulcers causing dysphagia and difficulty feeding in affected children. Genital primary HSV-2 presents with severe pain, dysuria, and systemic symptoms lasting 7-14 days. Recurrent orofacial herpes begins with prodromal symptoms including tingling, itching, or pain at site of prior herpes, followed within 24 hours by grouped vesicles on erythematous base, predominantly affecting vermillion border of lips or perioral skin. Vesicles rupture within 2-3 days leaving shallow ulcers that gradually dry and crust, with complete resolution within 7-10 days. Recurrent genital herpes presents similarly with painful vesicles on genitalia, often associated with dysuria, and resolving within 7-10 days. Atypical presentations occur in immunocompromised patients, who may develop extensive erosions and chronic ulceration. Herpes simplex keratitis affects cornea causing ocular pain, photophobia, and risk of scarring. Disseminated cutaneous or visceral herpes occurs rarely in severely immunosuppressed patients. Eczema herpeticum develops when primary HSV infection occurs in individuals with atopic dermatitis, causing widespread vesiculation, systemic symptoms, and risk of disseminated infection requiring IV antiviral therapy.

Diagnosis

Clinical diagnosis of herpes simplex typically relies on characteristic vesicular eruption in grouped pattern on erythematous base in characteristic distribution. Confirmation via laboratory testing improves diagnostic certainty, particularly for atypical presentations or primary infection. Viral culture remains gold standard for organism identification, though requires 2-7 days for results. Specimen collection from freshly opened vesicles yields highest sensitivity (90%+). PCR testing of vesicular fluid demonstrates highest sensitivity (95%+) with rapid turnaround time (within 24 hours), making it preferred test in many settings. Gram staining of Tzanck smear from base of vesicle reveals multinucleated giant cells consistent with HSV or varicella-zoster virus but cannot differentiate between these viruses. Direct fluorescent antibody (DFA) testing using monoclonal antibodies against HSV-1 and HSV-2 provides rapid results (1-2 hours) with moderate sensitivity (70-80%). HSV serologic testing using enzyme-linked immunosorbent assay (ELISA) identifies IgG antibodies for past infection or IgM antibodies for primary infection, though presence of IgG cannot differentiate primary from recurrent infection. Type-specific serology can distinguish HSV-1 from HSV-2. In primary genital infection, IgM positivity supports primary rather than recurrent disease. Histopathological examination demonstrates intraepidermal acantholysis with multinucleated giant cells and, if immunostaining performed, identifies HSV antigen.

Treatment Algorithm

Antiviral therapy with nucleoside analogs dramatically reduces symptom duration, viral shedding, and transmission risk in both primary and recurrent herpes simplex. Acyclovir 400 mg orally five times daily for 7-10 days (for primary infection) or 5 days (for recurrent) represents standard therapy. Valacyclovir 1000 mg orally three times daily for 7 days provides more convenient dosing than acyclovir due to superior bioavailability. Famciclovir 500 mg orally three times daily for 7 days provides comparable efficacy. IV acyclovir 5-10 mg/kg IV every 8 hours is reserved for severe disease, disseminated infection, or CNS involvement. Suppressive therapy with acyclovir 400-800 mg twice daily, valacyclovir 500 mg daily, or famciclovir 250 mg twice daily reduces recurrence frequency by 70-80% in frequently affected individuals. Suppressive therapy particularly beneficial in immunocompromised individuals or those in relationships where unaware transmission risk exists. Topical antivirals including acyclovir 5% cream applied five times daily provide minimal benefit compared to systemic therapy and are not recommended as primary treatment. Pain management with analgesics including acetaminophen or ibuprofen addresses discomfort. Topical anesthetics including lidocaine provide symptomatic relief. Management of systemic symptoms in primary infection including fever and myalgias with nonsteroidal anti-inflammatory drugs and rest facilitates recovery. Patients should be counseled regarding transmission risk, with avoidance of sexual contact during prodromal symptoms or vesicular eruption in genital disease.

Prognosis

Prognosis for herpes simplex infection is excellent in immunocompetent individuals, with primary infection resolving within 2-3 weeks and recurrent disease within 7-10 days. Antiviral therapy reduces duration by approximately 1-2 days when initiated early (within 72 hours of symptom onset). Suppressive antiviral therapy prevents approximately 70-80% of recurrent episodes. Transmission risk to partners remains 1-3% annually even with suppressive therapy. Most individuals experience decreasing frequency of recurrent episodes over time, with many patients having minimal or no recurrences after 5-10 years. Complications including keratitis, meningitis, or disseminated disease occur rarely in immunocompetent individuals. Immunocompromised patients including those with advanced HIV disease (CD4 less than 50), solid organ transplant recipients, or those on high-dose immunosuppressive therapy demonstrate markedly higher risk of severe, prolonged disease with potential for chronic ulceration and tissue necrosis if untreated. Long-term suppressive antiviral therapy prevents recurrent disease in immunocompromised populations.

When to See a Dermatologist

Patients with frequent recurrent herpes simplex (more than 6 recurrences yearly) should seek dermatology consultation to discuss suppressive therapy options. Those with atypical presentations, diagnostic uncertainty, or complications warrant specialist evaluation. Patients with disseminated disease, CNS involvement, or severe disease in immunocompromised individuals require urgent evaluation and possible hospitalization.

Frequently Asked Questions

Q: Can herpes simplex be cured?
A: No, HSV infection cannot be completely eliminated as virus remains dormant in nerve cell ganglia. However, antiviral therapy controls viral replication and suppressive therapy prevents most recurrent episodes.

Q: Is herpes simplex contagious between recurrences?
A: Yes, HSV can be transmitted even without visible lesions through asymptomatic viral shedding. Risk is highest during prodromal symptoms or vesicular eruption but continues at lower level even when asymptomatic.

Q: Can genital herpes be transmitted to the mouth?
A: Yes, HSV-2 can be transmitted to oral sites through oral-genital contact. However, oral HSV-1 is more common than HSV-2 in mouth infections.

Q: Does antiviral therapy prevent transmission?
A: Suppressive antiviral therapy reduces but does not eliminate transmission risk. Transmission risk decreases by approximately 50% with suppressive therapy combined with consistent condom use.

References

  1. Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antiviral Res. 2006;71(2-3):141-148.
  2. Corey L, Wald A. Genital herpes. In: Knipe DM, Howley PM, editors. Fields Virology. 6th ed. Philadelphia: Wolters Kluwer; 2013. p. 1944-1995.
  3. Looker KJ, Garnett GP. A systematic review of the epidemiology of herpes simplex virus-2 infection in sub-Saharan Africa. Sex Transm Dis. 2005;32(1):7-16.
  4. Drake MJ, Cowan FO, Wald A. Strategies for managing herpes simplex virus infection: implications of viral transmission and emerging antivirals. Mayo Clin Proc. 2008;83(3):300-309.
  5. Wald A, Corey L. Persistence in the population: epidemiology, transmission, and disease associations. J Clin Virol. 2002;25(Suppl 2):S25-S35.
  6. Johnston C, Saracino M, Kuntz S, et al. Standard-dose and high-dose daily oral acyclovir therapy for episodic treatment of genital herpes: efficacy and tolerability. J Infect Dis. 2012;206(10):1504-1511.
  7. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infection: an evidence-based review. Arch Intern Med. 2008;168(11):1137-1144.
  8. Cunningham AL, Lee FK, Ho DW, et al. Herpes simplex virus type 1 glycoprotein G antigen is useful for serological diagnosis and seroepidemiological studies. J Clin Microbiol. 1988;26(3):464-467.
  9. Goldmeier D, Madden M. Management of genital herpes in 2006. Int J STD AIDS. 2006;17(2):74-78.
  10. Astruc B, Dumont R, Monnat K. Antiviral therapy and prevention of herpes simplex virus disease. Expert Rev Anti Infect Ther. 2011;9(9):1013-1024.